Tonix Pharmaceuticals Holding Corp. (TNXP)
$
34.92
-2.05 (-5.87%)
Key metrics
Financial statements
Free cash flow per share
-10.1138
Market cap
235.3 Million
Price to sales ratio
23.4323
Debt to equity
0.0031
Current ratio
12.3146
Income quality
0.4508
Average inventory
8.3 Million
ROE
-1.0553
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and licensing of therapeutics and diagnostics aimed at treating and preventing human diseases while alleviating suffering. The company's diverse portfolio encompasses areas such as immunology, rare diseases, infectious diseases, and central nervous system (CNS) product candidates. Within its immunology portfolio, Tonix includes biologics designed to tackle organ transplant rejection, autoimmunity, and cancer, with notable candidates like TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, currently in development for the prevention of allograft and xenograft rejection, as well as for the treatment of autoimmune diseases. Furthermore, its rare disease portfolio features TNX-2900, which is aimed at treating Prader-Willi syndrome. The infectious disease pipeline encompasses TNX-801, a vaccine intended to prevent smallpox and monkeypox; TNX-1840 and TNX-1850, live virus vaccines derived from the recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug developed to manage acute COVID-19; and TNX-102 SL, targeting Long COVID, a chronic post-acute COVID-19 condition. Additionally, Tonix’s CNS portfolio includes various small molecules and biologics for pain, neurologic, psychiatric, and addiction treatment, featuring TNX-102 SL, currently in mid-Phase 3 trials for fibromyalgia management; TNX-1900, aimed at preventing migraine headaches; and TNX-1300, which is designed to address cocaine intoxication. Founded in 2007 and headquartered in Chatham, New Jersey, the company incurred an income tax expense of -$1,167,000.00 indicating its tax obligations. The total costs and expenses for the company are $87,838,000.00 reflecting its overall spending. The diluted EPS is -$3,504.00 accounting for potential share dilution. The company reported selling, general, and administrative expenses of $40,101,000.00 indicating its operational overhead costs, along with depreciation and amortization expenses of $3,421,000.00 which reflect the wear and tear of its assets. In the current market environment, the stock is affordable at $34.92 making it suitable for budget-conscious investors. Notably, the stock exhibits a high average trading volume of 1,187,526.00 indicating strong liquidity that may attract investors. With a market capitalization of $256,913,424.00 the company is categorized as a small-cap player. It holds a significant position in the Biotechnology industry, contributing meaningfully to the overall market landscape. Furthermore, the company belongs to the Healthcare sector, which is essential in driving innovation and fostering growth within the biopharmaceutical field.
Is Tonix Pharmaceuticals Holding Corp. (TNXP) a good investment?
Investing in Tonix Pharmaceuticals Holding Corp. (TNXP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Tonix Pharmaceuticals Holding Corp. (TNXP)'s stock forecast?
Analysts predict Tonix Pharmaceuticals Holding Corp. stock to fluctuate between $6.76 (low) and $137 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tonix Pharmaceuticals Holding Corp.'s market capitalization?
As of 2025-06-17, Tonix Pharmaceuticals Holding Corp.'s market cap is $256,913,424, based on 7,357,200 outstanding shares.
How does Tonix Pharmaceuticals Holding Corp. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Tonix Pharmaceuticals Holding Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tonix Pharmaceuticals Holding Corp. (TNXP) stock?
To buy Tonix Pharmaceuticals Holding Corp. (TNXP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TNXP. Place an order (Market, Limit, etc.).
What is the best time to invest in Tonix Pharmaceuticals Holding Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Tonix Pharmaceuticals Holding Corp. stock ever split?
Tonix Pharmaceuticals Holding Corp.'s last stock split was 1:100 on 2025-02-05.
How did Tonix Pharmaceuticals Holding Corp. perform in the last earnings report?
Revenue: $10,094,000 | EPS: -$3,504 | Growth: -44.98%.
Where can I find Tonix Pharmaceuticals Holding Corp.'s investor relations reports?
Visit https://www.tonixpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tonix Pharmaceuticals Holding Corp.?
You can explore historical data from here
What is the all-time high and low for Tonix Pharmaceuticals Holding Corp. stock?
All-time high: $1,356,800 (2021-02-11) | All-time low: $6.76 (2025-03-04).
What are the key trends affecting Tonix Pharmaceuticals Holding Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved market; FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue. Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage in this market.
seekingalpha.com
Tonix Pharmaceuticals' TNX-102 SL shows a high probability of FDA approval for fibromyalgia, supported by positive Phase 3 trials and an acceptable safety profile. A recent $500M shelf offering caused a stock dip but does not impact approval odds; current valuation does not include TNX-102 approval. Risks include modest efficacy and challenging market adoption; therefore, we recommend buying TNXP stock before PDUFA and reassessing before commercial launch.
globenewswire.com
Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis
globenewswire.com
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years
seekingalpha.com
PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Committee Meeting of TNX-102 SL for the treatment of patients with Fibromyalgia. TNX-102 SL met primary endpoints in two Phase 3 studies, showing significant pain reduction, positioning it as the first new Fibromyalgia drug in 15 years.
globenewswire.com
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonstrated single-dose immune protection against a monkeypox challenge in non-human primates Received first payments from U.S. Department of Defense (DoD) contract for up to $34 million over five years to develop a broad-spectrum antiviral drug program CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent operational highlights.
See all news
